CN111450257A - 基于zif-8和核黄素的复合纳米材料及其制备方法和应用 - Google Patents
基于zif-8和核黄素的复合纳米材料及其制备方法和应用 Download PDFInfo
- Publication number
- CN111450257A CN111450257A CN202010191382.6A CN202010191382A CN111450257A CN 111450257 A CN111450257 A CN 111450257A CN 202010191382 A CN202010191382 A CN 202010191382A CN 111450257 A CN111450257 A CN 111450257A
- Authority
- CN
- China
- Prior art keywords
- riboflavin
- zif
- nano material
- composite nano
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title claims abstract description 84
- 229960002477 riboflavin Drugs 0.000 title claims abstract description 60
- 239000002151 riboflavin Substances 0.000 title claims abstract description 60
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 43
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 239000002131 composite material Substances 0.000 title claims abstract description 42
- 235000019192 riboflavin Nutrition 0.000 title claims abstract description 42
- 239000013154 zeolitic imidazolate framework-8 Substances 0.000 title claims abstract description 25
- MFLKDEMTKSVIBK-UHFFFAOYSA-N zinc;2-methylimidazol-3-ide Chemical compound [Zn+2].CC1=NC=C[N-]1.CC1=NC=C[N-]1 MFLKDEMTKSVIBK-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 36
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims abstract description 12
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000012621 metal-organic framework Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 5
- 238000013329 compounding Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 15
- 239000003889 eye drop Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 18
- 210000000981 epithelium Anatomy 0.000 abstract description 16
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 201000002287 Keratoconus Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 206010011033 Corneal oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 201000004778 corneal edema Diseases 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了基于ZIF‑8和核黄素的复合纳米材料及其制备方法和应用,其技术方案包括将核黄素分散到2‑甲基咪唑的甲醇溶液中,在搅拌的情况下加入硝酸锌的甲醇溶液,在室温条件下搅拌均匀,2‑甲基咪唑与硝酸锌反应合成正电位和脂溶性的ZIF‑8金属有机框架材料,且该合成过程中该ZIF‑8金属有机框架材料为载体复合携带负电位的核黄素,得到复合纳米材料。采用上述方法制备的ZIF‑8‑核黄素复合纳米材料,利用正电位的脂溶性的ZIF‑8金属有机框架材料携带负电位的核黄素,跟带负电荷的眼表上皮粘附并透过上皮,其在未去上皮情况下的交联效果几乎可以达到去上皮的核黄素交联效果,具有重要的研究意义和临床应用价值。
Description
技术领域
本发明属于生物医学材料和纳米材料科学领域,具体是指基于ZIF-8和核黄素的复合纳米材料及其制备方法和应用。
背景技术
圆锥角膜是一种角膜的非感染性变性疾病,多于青春期发病,可顿挫性或进行性缓慢发展。它常造成不规则近视散光及高度近视,晚期会出现角膜后弹力层破裂、急性角膜水肿,形成混浊瘢痕,视力显著下降,此阶段要改善视力只能行角膜移植术。核黄素/紫外光(370nm)角膜交联术被认为是一种能有效控制圆锥角膜进展的治疗方法,其原理是渗入角膜基质的核黄素与紫外光相互作用,产生一种活性氧组的物质,这种物质可以诱导胶原纤维,产生化学交联反应,从而使角膜纤维增粗,角膜细胞凋亡,提高角膜对其它一些酶抵抗效应,从而防止圆锥角膜进一步发展造成更严重的角膜以及视力的损害。
由于角膜上皮的特殊结构及药物核黄素难透上皮的特性,目前临床用常用的交联手术多是去上皮角膜胶原交联术,并取得了良好的临床效果。去上皮角膜胶原交联术有利于角膜基质对核黄素的吸收而增强角膜胶原的交联强度,但增加了术后感染的发生概率和角膜上皮修复时间,在术后24-48h,术眼会有强烈的异物感、烧灼感和流泪,少数患者甚至出现角膜水肿及角膜大面积的薄雾;而保留角膜上皮的交联术则基本消除以上并发症。
因此研究可透上皮的核黄素药物试剂具有重要研究意义及应用价值。基于此,本发明人经过创造性研究,提出本项发明创造。
发明内容
为解决现有技术存在的问题和不足,本发明的目的是提供一种基于ZIF-8和核黄素的复合纳米材料及其制备方法,该复合纳米材料可以提高核黄素透上皮能力并提高角膜交联效果,从而在保留角膜上皮的交联术中作为药物载体具有非常重要的临床价值。
为实现上述目的,本发明的第一个方面是将核黄素分散到2-甲基咪唑的甲醇溶液中,在搅拌的情况下加入硝酸锌的甲醇溶液,在室温条件下搅拌均匀,2-甲基咪唑与硝酸锌反应合成正电位和脂溶性的ZIF-8金属有机框架材料,且该合成过程中该ZIF-8金属有机框架材料为载体复合携带负电位的核黄素,得到复合纳米材料。
进一步设置是将120-360mg的2-甲基咪唑和不同量的核黄素分散到10ml的甲醇溶液中,搅拌均匀后,将10ml含有60-240mg硝酸锌的甲醇溶液加入上述溶液中,继续搅拌4-6h,离心得到复合纳米材料。
另外,本发明还提供一种如所述的制备方法所制备的基于ZIF-8和核黄素的复合纳米材料。
此外,本发明还提供一种用于保留上皮的角膜交联术的眼药水,该眼药水包含有权利要求3所述的基于ZIF-8和核黄素的复合纳米材料。
将所制备的ZIF-8-核黄素复合纳米材料的水溶液滴到兔子的眼表,浸润时间为30-60min,之后用30mW,波长为365nm的UV灯照射30min,期间每隔5min补滴一次ZIF-8-核黄素复合纳米材料溶液,检测光照后的角膜交联效果。我们发现所合成的ZIF-8-核黄素复合纳米材料在紫外光的照射下具有显著的角膜胶原交联效果。
本发明的有益效果是:采用上述方法制备的ZIF-8-核黄素复合纳米材料,利用正电位的脂溶性的ZIF-8金属有机框架材料携带负电位的核黄素,跟带负电荷的眼表上皮粘附并透过上皮,其在未去上皮情况下的交联效果几乎可以达到去上皮的核黄素交联效果,具有重要的研究意义和临床应用价值。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动性的前提下,根据这些附图获得其他的附图仍属于本发明的范畴。
图1为本发明制得的ZIF-8、ZIF-8-核黄素复合纳米材料及核黄素红外图谱;
图2为本发明实例制得的ZIF-8,ZIF-8-核黄素复合纳米材料的SEM照片;
图3为本发明实例制得的ZIF-8-核黄素复合纳米材料与纯的核黄素在未去上皮的情况下的角膜胶原交联效果对比图;
图4为本发明实例制得的ZIF-8-核黄素复合纳米材料在未去上皮的情况下的角膜胶原交联效果与临床上去上皮核黄素角膜胶原交联效果对比图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合附图对本发明作进一步地详细描述。
首先将120-360mg的2-甲基咪唑和不同量的核黄素分散到10ml的甲醇溶液中(其中核黄素的浓度控制在1-5mg/mL),搅拌均匀后,将10ml含有60-240mg硝酸锌的甲醇溶液加入上述溶液中,继续搅拌4-6h,离心得到复合纳米材料。
将所制备的ZIF-8-核黄素复合纳米材料的水溶液滴到兔子的眼表,浸润时间为30-60min,之后用30mW,波长为365nm的UV灯照射30min,期间每隔5min补滴一次ZIF-8-核黄素复合纳米材料溶液,检测光照后的角膜交联效果。
由图1ZIF-8,ZIF-8-核黄素复合纳米材料及核黄素红外图谱可以确认所得IF-8-核黄素复合纳米材料中ZIF-8和核黄素两种物质同时存在。
由图2左右照片分别为ZIF-8,ZIF-8-核黄素复合纳米材料的SEM照片,可见所得ZIF-8-核黄素复合纳米材料仍具有很小的粒径和很好的分散性。
由图3ZIF-8-核黄素复合纳米材料与纯的核黄素在未去上皮的情况下的角膜胶原交联效果对比图,可以发现所合成的ZIF-8-核黄素复合纳米材料可以透过上皮,并进行角膜胶原交联,而核黄素在未去上皮的情况下透上皮能力很差,这说明ZIF-8载体的加入有利于核黄素透过上皮。
由图4ZIF-8-核黄素复合纳米材料在未去上皮的情况下的角膜胶原交联效果与纯的核黄素在去上皮的情况下的角膜胶原交联效果对比图,可以发现所合成的ZIF-8-核黄素复合纳米材料在未去上皮的情况下角膜胶原交联效果接近于临床上用的去上皮核黄素角膜胶原交联效果,具有良好的角膜胶原交联效果。
以上所揭露的仅为本发明较佳实施例而已,当然不能以此来限定本发明之权利范围,因此依本发明权利要求所作的等同变化,仍属本发明所涵盖的范围。
Claims (4)
1.一种基于ZIF-8和核黄素的复合纳米材料的制备方法,其特征在于:
将核黄素分散到2-甲基咪唑的甲醇溶液中,在搅拌的情况下加入硝酸锌的甲醇溶液,在室温条件下搅拌均匀,2-甲基咪唑与硝酸锌反应合成正电位和脂溶性的ZIF-8金属有机框架材料,且该合成过程中ZIF-8金属有机框架材料为载体复合携带负电位的核黄素,得到复合纳米材料。
2.根据权利要求1所述的基于ZIF-8和核黄素的复合纳米材料的制备方法,其特征在于:将120-360mg的2-甲基咪唑和不同量的核黄素分散到10ml的甲醇溶液中,搅拌均匀后,将10ml含有60-240mg硝酸锌的甲醇溶液加入上述溶液中,继续搅拌4-6h,离心得到复合纳米材料。
3.一种如权利要求1-2之一所述的制备方法所制备的基于ZIF-8和核黄素的复合纳米材料。
4.一种用于保留上皮的角膜交联术的眼药水,其特征在于:该眼药水包含有权利要求3所述的基于ZIF-8和核黄素的复合纳米材料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010191382.6A CN111450257A (zh) | 2020-03-18 | 2020-03-18 | 基于zif-8和核黄素的复合纳米材料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010191382.6A CN111450257A (zh) | 2020-03-18 | 2020-03-18 | 基于zif-8和核黄素的复合纳米材料及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111450257A true CN111450257A (zh) | 2020-07-28 |
Family
ID=71671906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010191382.6A Pending CN111450257A (zh) | 2020-03-18 | 2020-03-18 | 基于zif-8和核黄素的复合纳米材料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111450257A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113061270A (zh) * | 2021-04-01 | 2021-07-02 | 华南理工大学 | 可生物降解的uva光响应型控释抗菌食品包装薄膜及制备方法与应用 |
CN114848830A (zh) * | 2022-04-26 | 2022-08-05 | 复旦大学附属眼耳鼻喉科医院 | 一种用于提高角膜交联效果的制剂及角膜交联组合制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014174544A1 (en) * | 2013-04-24 | 2014-10-30 | Medivis S.R.L. | Riboflavin formulations for trans-epithelial cross-linking |
CN108329486A (zh) * | 2018-05-09 | 2018-07-27 | 北京化工大学 | 一种介孔杂化结构的金属有机骨架材料的制备方法和应用 |
CN110721748A (zh) * | 2019-11-07 | 2020-01-24 | 山东大学 | 一种光催化剂及其制备方法和应用 |
-
2020
- 2020-03-18 CN CN202010191382.6A patent/CN111450257A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014174544A1 (en) * | 2013-04-24 | 2014-10-30 | Medivis S.R.L. | Riboflavin formulations for trans-epithelial cross-linking |
CN108329486A (zh) * | 2018-05-09 | 2018-07-27 | 北京化工大学 | 一种介孔杂化结构的金属有机骨架材料的制备方法和应用 |
CN110721748A (zh) * | 2019-11-07 | 2020-01-24 | 山东大学 | 一种光催化剂及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
AGRAWAL, VINAY等: "Long-term results of cornea collagen cross-linking with riboflavin for keratoconus", INDIAN JOURNAL OF OPHTHALMOLOGY, vol. 61, no. 8, pages 433 - 434, XP009176739, DOI: 10.4103/0301-4738.116072 * |
侯爱萍: ""角膜交联治疗圆锥角膜的方法及临床效果分析", 山西医药杂志, vol. 47, no. 12, pages 1436 - 1438 * |
王辉: "角膜胶原交联术的应用研究", 医学信息, vol. 32, no. 13, pages 46 - 48 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113061270A (zh) * | 2021-04-01 | 2021-07-02 | 华南理工大学 | 可生物降解的uva光响应型控释抗菌食品包装薄膜及制备方法与应用 |
CN113061270B (zh) * | 2021-04-01 | 2021-12-17 | 华南理工大学 | 可生物降解的uva光响应型控释抗菌食品包装薄膜及制备方法与应用 |
CN114848830A (zh) * | 2022-04-26 | 2022-08-05 | 复旦大学附属眼耳鼻喉科医院 | 一种用于提高角膜交联效果的制剂及角膜交联组合制剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111450257A (zh) | 基于zif-8和核黄素的复合纳米材料及其制备方法和应用 | |
US20210079170A1 (en) | Preparation method of 4d chitosan-based thermosensitive hydrogel | |
CN108480650A (zh) | 一种液态金属纳米颗粒及其制备方法 | |
CN106964321B (zh) | 一种香蕉纤维壳聚糖复合水凝胶的制备方法及其应用 | |
CN109432123B (zh) | 一种复方电解质葡萄糖注射液及其制备方法 | |
CN103071189A (zh) | 一种组织引导再生用胶原膜的制备方法 | |
CN113197843A (zh) | 一种多巴胺涂覆的纤维素纳米晶-琼脂糖载药水凝胶及其制备方法 | |
CN1973911A (zh) | 结构仿生的角膜组织工程支架的制备方法 | |
CN110772662A (zh) | 一种抗菌膨体聚四氟乙烯面部植入材料及其制备工艺 | |
CN1466952A (zh) | 治疗皮肤炎之外用剂 | |
CN107185038A (zh) | 一种表面固定化改性角膜修复材料及其制备方法 | |
CN107115564A (zh) | 一种制备载氧化铈纳米粒子功能膜层的纯钛种植体材料的方法 | |
CN113754903B (zh) | 一种用于皮肤修复的双交联透明质酸/壳聚糖复合水凝胶的制备方法 | |
CN106138011B (zh) | 碳酸钙/透明质酸复合药物载体及其制备方法 | |
CN112957321B (zh) | 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法 | |
CN109265708A (zh) | 一种用于装载细胞的氧化石墨烯修饰基复合材料E-cGO/Alg及其制备方法、应用 | |
CN1895275A (zh) | 一种小牛血去蛋白提取物凝胶剂 | |
CN113304309A (zh) | 用于伤口皮肤修复的复方水凝胶贴片及其制备方法 | |
CN114848830A (zh) | 一种用于提高角膜交联效果的制剂及角膜交联组合制剂 | |
CN116763722B (zh) | 水凝胶制备材料、水凝胶材料及其制备方法与应用 | |
CN107858339B (zh) | 一种抑制淀粉酶活性的方法 | |
CN116688120A (zh) | 一种角膜交联术用光敏剂及其制备方法 | |
CN1954855A (zh) | 含玻璃酸钠的治疗眼底黄斑变性的眼用制剂及其制备方法 | |
CN112999145B (zh) | 一种负载曲安奈德的水凝胶复合物的制备方法及应用 | |
CN114984241B (zh) | 一种壳聚糖/二氧化锰/葡萄糖氧化酶纳米复合材料及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned | ||
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20240319 |